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a comparison of bleeding complications of
patients with different oral anticoagulants
Martin Müller1, Michaela Traschitzger1, Michael Nagler2, Spyridon Arampatzis3, Aristomenis K. Exadaktylos1 and
Thomas C. Sauter1*
Abstract
Background: Up to a fourth of patients at emergency department (ED) presentation suffer from acute deterioration
of renal function, which is an important risk factor for bleeding events in patients on oral anticoagulation therapy.
We hypothesized that outcomes of patients, bleeding characteristics, therapy, and outcome differ between direct
oral anticoagulants (DOACs) and vitamin-K antagonists (VKAs).
Methods: All anticoagulated patients older than 17 years with an impaired kidney function treated for an acute
haemorrhage in a large Swiss university ED from 01.06.2012 to 01.07.2017 were included in this retrospective cohort
study. Patient, treatment, and bleeding characteristics as well as outcomes (length of stay ED, intensive care unit
and in-hospital admission, ED resource consumption, in-hospital mortality) were compared between patients on
DOAC or VKA anticoagulant.
Results: In total, 158 patients on DOAC and 419 patients on VKA with acute bleeding and impaired renal function
were included. The renal function in patients on VKA was significantly worse compared to patients on DOAC (VKA:
median 141 μmol/L vs. DOAC 132 μmol/L, p = 0.002). Patients on DOAC presented with a smaller number of
intracranial bleeding compared to VKA (14.6% DOAC vs. 22.4% VKA, p = 0.036). DOAC patients needed more
emergency endoscopies (15.8% DOAC vs, 9.1% VKA, p = 0.020) but less interventional emergency therapies to stop
the bleeding (13.9% DOAC vs. 22.2% VKA, p = 0.027). Investigated outcomes did not differ significantly between the
two groups.
Conclusions: DOAC patients were found to have a smaller proportional incidence of intracranial bleedings, needed
more emergency endoscopies but less often interventional therapy compared to patients on VKA. Adapted
treatment algorithms are a potential target to improve care in patients with DOAC.
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Background
Any type of anticoagulation is associated with the risk
of bleeding complications [1]. Frequency of bleeding
and bleeding locations, however, may differ among
different classes of anticoagulants. Intracranial haem-
orrhage and gastrointestinal bleedings (GIB) are the
most common bleeding complications leading to
major haemorrhage in patients on direct oral antico-
agulants (DOAC) therapy [2]. Compared to classic
vitamin K antagonist therapy (VKA), DOAC were
found to be associated with a 50% reduction of intra-
cranial haemorrhage [3, 4]. In contrast to intracranial
haemorrhage, the incidence of GIB in DOAC patients
is at least comparable to VKA or may be even higher
for dabigatran and rivaroxaban [5].
Treatment of special patient groups with the need of
anticoagulation e.g. patients with chronic kidney diseases
(CKD) or at risk for CKD [2, 6] may be more demand-
ing. Patients with atrial fibrillation and CKD are a special
treatment challenge, because they combine an increasing
risk of both, bleeding in general and thrombotic compli-
cations [7, 8]. A previous study found major bleeding
events in elderly patients on DOAC therapy to be associ-
ated with a decline of renal function [9]. All registered
DOAC are eliminated to a certain extent through the
kidneys and thus all have limitations in patients with
CKD [7]. However, recent clinical trials suggest that
DOAC may be also beneficial in comparison to VKA in
CKD patients [4, 10].
Current clinical guidelines recommend careful consid-
erations about the risk and benefit in patients with im-
paired kidney function and need for anticoagulation [11]
and specifically emphasis on the need of a stable situ-
ation to assess the kidney function and warn not to con-
fuse acute renal impairment with CKD [7]. In contrast
to this premise of a “stable situation”, up to a fourth of
patients with whom an emergency physician is con-
fronted at emergency department (ED) admission with
an acute medical problem suffer from acute deterior-
ation of renal function with unclear dimensions and dy-
namics [12]. This acute influence of situational
environmental factors is difficult to represent in classical
RCTs, which is why real-world data is needed for this
purpose [13, 14].
Therefore, our primary study aim is to analyse
bleeding and patient characteristics in patients with im-
paired kidney function at ED admission due to acute
haemorrhage on DOAC therapy and compare them to
patients on VKA. Furthermore, we investigate clinical
outcomes (in-hospital mortality) and procedural
outcomes, i.e. length of stay in the ED and in hospital,
intensive care unit (ICU) transmission and hospitalisa-
tion rate as well as ED resource consumption, all com-
pared to patients on VKA.
Methods
Study design & setting
This is a retrospective cohort study of the adult ED of
the Bern University Hospital, Inselspital, Switzerland.
Our ED is responsible for the emergency treatment of




This study included all patients treated for acute haem-
orrhage at our ED from 1st of June, 2012 to 30th of
June, 2017 with i) VKA or DOAC therapy for full antic-
oagulation and ii) an impaired kidney function at admis-
sion defined as an glomerular filtration rate (GFR) ≤60
mL/min [15].
Exclusion criteria
The exclusion criteria were i) no creatinine testing per-
formed at ED admission, ii) GFR > 60 mL/min at admis-
sion, iii) no oral anticoagulation medication documented
in the medical report, and iv) no acute bleeding compli-
cation at ED admission.
Primary and secondary outcomes
Primary study outcomes were bleeding and patient char-
acteristics on DOAC therapy compared to VKA.
Secondary outcomes were procedural outcomes
(length of stay in the ED and in hospital, ICU transmis-
sion and hospitalisation rate as well as ED resource con-
sumption) and clinical outcomes, i.e. in-hospital
mortality.
Definitions
The National Kidney Foundation Kidney Disease Out-
comes Quality Initiative (KDOQI) classification was used
for classification of kidney impairment [15], with the se-
verity grades according to the GFR of 45–60mL/min,
30-44 mL/min, 15-29 mL/min, and < 15mL/min. The
GFR was calculated using the CKD-EPI equation as it
was recommended by the National Kidney Foundation
because of the reliability across all CKD stages [16]. Al-
though the Cockroft-Gault equation for GFR estimation
was applied in the landmark clinical trials of DOAC in
atrial fibrillation, it has several limitation in its applica-
tion particularly in patients that are overweight and
older [7].. Since the implementation of the Cockroft-
Gault equation was not feasible in our retrospective ED
study as patient weight is not documented for all ED pa-
tients we performed the analysis using the CKD-EPI
equation which is calculated automated in all patients.
Polypharmacy was defined as the use of five or more
drugs [17].
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To describe comorbidities of a patient, the Charlson
comorbidity index was used including parameter such as
liver disease, CKD, diabetes, cerebrovascular disease, and
congestive heart failure [18].
Major bleeding were defined for our study according
to the international society of thrombosis and haemosta-
sis (ISTH) definition as fatal bleeding, symptomatic
bleeding in critical organ or transfusion of at least two
erythrocytes concentrates [19]. As a documented
haemoglobin drop of at least 20 g/L was not feasible to
determine reliable in the ED setting, the criterion was
not used.
In Switzerland, the costs incurred in an ED for each
ambulatory procedure or physician/nurse work are
settled in “tarmed: tarif médical” points which, is a sys-
tem of procedure codes. This point system used in
Switzerland corresponds to 1 Swiss franc per 1 point
billed. We indicate the total ED resource consumption
during treatment in “tax points” as the sum of all
procedures.
Data handling
A keyword search was performed through all medical
reports between 01.06.2012 to 01.07.2017 containing all
the substance classes and brand names of oral anticoag-
ulants approved in Switzerland (substance classes:
rivaroxaban, dabigatran, apixaban, and edoxaban, phen-
procoumon, warfarin, and acenocoumarol), combined
with the logic operator “OR”. Medical ED reports in our
department including patient history, diagnosis, clinical
findings, and medication administered are stored elec-
tronically in an ED patient database (E-Care, ED 2.1.3.0,
Turnhout, Belgium). We excluded all search results of
cases without creatinine testing at ED admission. Finally,
the eligibly criteria were evaluated by manual full text
analysis of each found medical ED report.
The following parameter were extracted directly
from the database: age, sex, triage level (which is rou-
tinely determined by special trained nurses using the
Swiss triage scale [20]), type of referral, all procedural
outcomes, in-hospital mortality, as well as creatinine
and INR values on admission. Using full-text analysis
of the medical report, the following parameter were
manually extracted: trauma, information on anticoagu-
lation (indication for therapy, type of medication, add-
itional antiplatelet therapy), comorbidities to calculate
the Charlson comorbidity index, arterial hypertension
and polypharmacy, bleeding characteristics i.e. loca-
tion and extent of bleeding (major bleeding and the
discharge diagnosis of a haemorrhage shock) as well
as information on the therapy of the bleeding. Inter-
ventional therapies included surgery, coiling, clipping,
embolization, angiography, drainage, and variceal
ligation. A diagnostic endoscopy was not considered
an interventional therapy.
Group description and data analysis
The DOAC group used for analysis combined all pa-
tients on any DOAC approved in Switzerland (apixaban,
dabigatran, edoxaban and rivaroxaban) on ED admission.
For group comparison we formed a VKA group, includ-
ing all patients under phenprocoumon and acenocu-
marol at ED admission. All statistical analysis for this
work was performed with Stata® 13.1 (StataCorp, The
College Station, Texas, USA).
For descriptive analysis the distribution of categorical
variables was presented as the absolute accompanied by
the relative number in each category [n (%)] and of con-
tinuous outcomes with the median accompanied by the
interquartile range (IQR) as normal distribution of con-
tinuous outcomes could not be ensured.
To compare the study groups (DOAC vs. VKA) Chi
square and Wilcoxon rank sum tests were used, as ap-
propriate. The significance level was set to p < 0.05. As
this is an exploratory data analysis, there was no adjust-
ment for multiple testing.
Ethical considerations
The present study is registered with the competent eth-
ics committee of Canton Bern, Switzerland under the
number 073/2015 and according to Swiss law, the need
to obtain informed consent for the study was waived.
Results
Anticoagulation key-word search between 01.06.2012 to
31.06.2017 resulted in 14,684 patients out of 199,982
consultations (Fig. 1).
In 2391 patients, no creatinine measurements were
performed during ED workup and 8435 patients had a
renal function above the cut-off value (GFR > 60ml/min)
and were therefore excluded.
By manual screening and exclusion of 3281 patients
without an acute diagnosis of bleeding (n = 3196), un-
clear or no-anticoagulation status at ED admission (n =
80), and five patients with irregular consultation docu-
mentation (e.g. duplicates), we finally included 158 ED
consultations on DOAC and 419 consultations on VKA.
The ratio between VKA and DOAC patients decreased
over the study years. While in the first year of the study
(2012/2013) 91.0% of the patients were on VKA, in the
last year of the study 58.2% (2016/2017) were on VKA
therapy (p < 0.001).
Patient characteristics
An overview of all patient characteristics is presented in
Table 1.
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Fig. 1 Flowchart. Abbreviations: DOAC, direct oral anticoagulant; VKA, Vitamin K antagonists
Table 1 Patient characteristics
DOAC (n=158) VKA (n=419) Total (n=577) p
Demographic data
Sex, male [n (%)] 88 (55.7) 239 (57.0) 327 (56.7) 0.771
Age, [median (IQR)] 79.0 (72-83) 79.0 (70-85) 79.0 (71-84) 0.774
Renal function
Creatinine, μmol/L [median (IQR)] 132 (110-162) 141 (118-193) 138 (115-182) 0.002
GFR group, [n (%)]
45-59 mL/min 61 (38.6) 131 (31.3) 192 (33.3)
30-44 mL/min 65 (41.1) 147 (35.1) 212 (36.7)
15-29 mL/min 31 (19.6) 110 (26.3) 141 (24.4)
<15 mL/min 1 (0.6) 31 (7.4) 32 (5.5) 0.002
Comorbidity
Charlson Comorbidity Index, [median (IQR)] 5 (4-7) 5 (4-7) 5 (4-7) 0.144
Diabetes, [n (%)] 45 (28.5) 123 (29.4) 168 (29.1) 0.837
Liver insufficiency, [n (%)] 9 (5.7) 9 (2.1) 18 (3.1) 0.029
Arterial hypertension, [n (%)] 109 (69.0) 306 (73.0) 415 (71.9) 0.335
Polypharmacy, [n (%)] 138 (87.3) 353 (84.2) 491 (85.1) 0.352
Abbreviations: DOAC direct oral anticoagulants, GFR glomerular filtration rate, IQR Interquartile range, VKA Vitamin-K antagonist
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There were no significant differences regarding gender and
age (p = 0.771 and p = 0.774) between both anticoagulation
groups (see Table 1). The renal function in patients on VKA
was significantly (p = 0.002) worse compared to patients on
DOAC. Especially in the GFR < 15mL/min group 7.4% pa-
tients were on VKA vs. 0.6% on DOAC. Significant more pa-
tients (p = 0.029) on DOAC (5.7%) had a documented liver
insufficiency compared to VKA (2.1%). The Charlson co-
morbidity index (CCI) had a median of 5 (IQR 4–7) points
in both groups (p = 0.143). There was no significant group
difference regarding polypharmacy (p = 0.352).
Consultation and anticoagulation characteristics
The type of referral or triage category was similar in
both two study groups (Table 2). Trauma was found
more often in VKA patients (32.9%, n = 138) compared
to DOAC patients (24.1%, n = 38, p = 0.039). In the
DOAC group, the majority of DOAC patients were on
rivaroxaban (n = 141, 89.2%). Nine patients were on
apixaban (5.7%), six on dabigatran (3.8%), and two
(1.3%) on edoxaban. In the VKA group, the majority of
415 patients were on phenprocoumon (99.0%); 4 patients
were on acenocumarol (1.0%). Regarding indication for
Table 2 Consultation and anticoagulation characteristics
DOAC (n = 158) VKA (n = 419) Total (n = 577) p
Consultation
Referral, [n (%)]
Ambulance 47 (29.7) 138 (32.9) 185 (32.1)
General Practitioner 15 (9.5) 41 (9.8) 56 (9.7)
External Hospital 32 (20.3) 75 (17.9) 107 (18.5)
Air Rescue 0 (0.0) 8 (1.9) 8 (1.4)
Walk-In 37 (23.4) 72 (17.2) 109 (18.9)
Internal Referral 5 (3.2) 10 (2.4) 15 (2.6)
No Information 22 (13.9) 75 (17.9) 97 (16.8) 0.282
Triage, [n (%)]
Life-threatening 29 (18.4) 72 (17.2) 101 (17.5)
Urgent conditions 71 (44.9) 194 (46.3) 265 (45.9)
Semi-urgent conditions 51 (32.3) 134 (32.0) 185 (32.1)
Non urgent conditions 3 (1.9) 8 (1.9) 11 (1.9)
Missing 4 (2.5) 11 (2.6) 15 (2.6) 0.998
Trauma 38 (24.1) 138 (32.9) 176 (30.5) 0.039
Anticoagulation
Medication, [n (%)]
Phenprocoumon 415 (99.0) 415 (71.9)
Acenocumarol 4 (1.0) 4 (0.7)
Rivaroxaban 141 (89.2) 141 (24.4)
Dabigatran 6 (3.8) 6 (1.0)
Apixaban 9 (5.7) 9 (1.6)
Edoxaban 2 (1.3) 2 (0.3) < 0.001
Reason OAK, [n (%)]
Mechanical valve 2 (1.3) 36 (8.6) 38 (6.6)
Venous embolism 34 (21.5) 59 (14.1) 93 (16.1)
Atrial fibrillation 85 (53.8) 202 (48.2) 287 (49.7)
Combination 17 (10.8) 56 (13.4) 73 (12.7)
Other 5 (3.2) 17 (4.1) 22 (3.8)
Unknown 15 (9.5) 49 (11.7) 64 (11.1) 0.009
INR 1.3 (1.1–1.5) 2.4 (1.7–3.3) 2.0 (1.3–3.0) < 0.001
Antiplatelet therapy, [n (%)] 52 (32.9) 121 (28.9) 173 (30.0) 0.346
Abbreviations: DOAC direct oral anticoagulants, OAK oral anticoagulation, VKA Vitamin-K antagonist
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anticoagulation, the most common indication for antic-
oagulation in all patients was atrial fibrillation (49.7%).
Significant group differences were found regarding
“mechanical heart valve” and “venous embolism” as indi-
cations for anticoagulation (p = 0.009). Additional anti-
platelet therapy did not differ significantly between the
two study groups (p = 0.346).
The median INR in patients with VKA was 2.4 (IQR:
1.7–3.3), and in patients with DOAC 1.3 (IQR 1.1.-1.5).
Using the INR range 2.0–3.0 to the definition of thera-
peutic range, 31.3% of the VKA patients were over and
34.4% were under the therapeutic range.
Bleeding characteristics
Apart from a higher number of intracranial bleedings in-
cluding intracerebral bleedings in the VKA group (22.4%
vs. 14.6% in DOAC patients, p = 0.036), no significant
differences in the distribution of bleeding locations were
found, see Table 3. The most common location was GIB
in both anticoagulation groups (DOAC 34.8% vs. VKA
28.6%, p = 0.135). The incidence of major bleeding
events did not differ significantly between the study
groups (p = 0.784). Major bleeding was not significantly
associated with the GFR in the DOAC (p = 0.723)
respectively VKA group (p = 0.795).
VKA patients needed a higher number of interventions
to stop the bleeding compared to DOAC (22.2% vs.
13.9%, p = 0.027) and a smaller number needed gastro-
duodenoscopies (VKA 9.1% vs. DOAC 15.8%, p = 0.020),
see Table 4.
Clinical outcomes
Most patients were treated in hospital (DOAC 92.4% vs.
VKA 90.2%, p = 0.431) and 42.0% were admitted to ICU
(DOAC 38.2% vs. VKA 43.4%, p = 0.264) without group
difference for both outcomes, see Table 5. No differ-
ences were observed regarding ED resource consump-
tion, LOS in hospital or the ED as well as in-hospital
mortality.
Discussion
In this study patients with impaired kidney function and
bleeding complications at ED admission, DOAC patients
were found to have a lower proportional incidence of
intracranial haemorrhage, needed more emergency en-
doscopies, but less interventional therapies to stop the
bleeding compared to patients on VKA therapy.
In our study, the group of patients with VKA therapy
in general had a worse renal function compared to
DOAC mostly due to patients with impaired kidney
Table 3 Distribution of bleeding characteristics of all included hemorrhages
DOAC (n = 158) VKA (n = 419) Total (n = 577) p
Location, [n (%)]a
Epistaxis 14 (8.9) 46 (11.0) 60 (10.4) 0.457
Oral 2 (1.3) 8 (1.9) 10 (1.7) 0.597
Intracranial 23 (14.6) 94 (22.4) 117 (20.3) 0.036
Thorax 5 (3.2) 8 (1.9) 13 (2.3) 0.365
Extremity 1 (0.6) 0 (0.0) 1 (0.2) 0.103
Gastrointestinal 55 (34.8) 119 (28.4) 174 (30.2) 0.135
Intraabdominal 3 (1.9) 5 (1.2) 8 (1.4) 0.518
Retroperitoneal 1 (0.6) 10 (2.4) 11 (1.9) 0.170
Superficial 26 (16.5) 77 (18.4) 103 (17.9) 0.591
Intraocular 0 (0.0) 2 (0.5) 2 (0.3) 0.384
Intraarticular 1 (0.6) 6 (1.4) 7 (1.2) 0.434
Intraspinal 1 (0.6) 1 (0.2) 2 (0.3) 0.472
Intramuscular 4 (2.5) 25 (6.0) 29 (5.0) 0.092
Gross haematuria 18 (11.4) 34 (8.1) 52 (9.0) 0.220
Haemoptysis 3 (1.9) 7 (1.7) 10 (1.7) 0.851
Other location 22 (13.9) 41 (9.8) 63 (10.9) 0.155
Extent of bleeding, [n (%)]
Haemorrhagic shock 10 (6.3) 21 (5.0) 31 (5.4) 0.531
Major bleeding 67 (42.4) 183 (43.7) 250 (43.3) 0.784
Abbreviation: DOAC direct oral anticoagulants, VKA Vitamin-K antagonist
a the study population is by definition made of patients admitted for major hemorrhage, thus less frequent occurrence of one variable might be caused by a
higher frequency of another variable and vice versa
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function with GFR < 15ml/min, a range with very
limited experience with DOAC and contraindications for
most DOAC. A relevant number of patients on DOAC
therapy were found to have a renal function < 30ml/min
at admission that might potentially lead to accumulation
of anticoagulant medications [21]. This finding under-
lines the fact that all of the DOAC have dosing regimens
that need close monitoring of the renal function which
have be taken into account for selection of the correct
dosage.
In such patients current prescribing patterns may lead
to increased thrombo-embolic risk and increased bleed-
ing complications thus measurement of serum DOAC
levels might be useful to guide acute treatment as well
as further dose adjustments.
Additional platelet aggregation inhibitor therapy that
could further increase the risk of bleeding and is associ-
ated with a higher and more severe bleeding risk [22, 23]
was similarly distributed between the study groups.
Bleeding location and therapy
Most of the bleeding locations occurred in a com-
parable frequency in both, DOAC and VKA patients
with impaired renal function. GIB are a typical
bleeding location for DOAC especially on rivaroxa-
ban therapy [24]. For both anticoagulant groups, GIB
were the most common bleeding leading to ED ad-
mission in our study. Intracranial bleedings were
more prevalent in the VKA group. As the study
population consisted of patients admitted for major
hemorrhage, less frequent occurrence of one
bleeding location might be caused by a higher fre-
quency of another bleeding location and vice versa.
Thus, only proportional incidences could be deter-
mined in this study.
Patients with GIB under DOAC therapy received more
endoscopies overall and especially more gastroscopies
compared to VKA, although VKA patients received
more interventional therapies. Several reasons might ex-
plain these findings. First, physicians’ management of
DOAC-associated bleedings might differ as the specific
reversal agents of DOACs are expensive and may not be
available in some ED. Therefore, treating physicians are
more cautious as a multi-nominal survey about bleeding
management demonstrated [25]. This fact is reflected by
another study of our group that found an increased ap-
plication of prothrombin complex concentrates for re-
versal of DOAC compared to VKA bleedings in clinical
practice [26]. A recent meta-analysis of PCC and
andexanet alfa for management of factor Xa inhibitor re-
lated bleeding, found similar rates of good hemostasis
for both medications but a tendency to higher complica-
tion rates on andexanet alfa [27]. Second, several studies
suggested a higher rate of GIB in DOAC patients [5, 28],
thus, a wait-and-see approach might seem an inappro-
priate choice for the attending physician in DOAC pa-
tients with suspected GIB as the extend of the bleeding
in often unclear. Third, VKA reversal is straightforward
und routinely measurable compared to DOAC, thus,
some interventional procedures might have been per-
formed in VKA patients, while DOAC interventions
were postponed.
Table 4 Therapy of bleeding
DOAC (n = 158) VKA (n = 419) Total (n = 577) p
Therapy interventional, [n (%)] 22 (13.9) 93 (22.2) 115 (19.9) 0.027
Gastroduodenoscopy needed, [n (%)] 25 (15.8) 38 (9.1) 63 (10.9) 0.020
Colorectoscopy needed, [n (%)] 6 (3.8) 12 (2.9) 18 (3.1) 0.565
Bronchoscopy needed, [n (%)] 1 (0.6) 0 (0.0) 1 (0.2) 0.103
Abbreviations: DOAC direct oral anticoagulants, VKA Vitamin-K antagonist
Table 5 Secondary outcomes
DOAC (n = 158) VKA (n = 419) Total (n = 577) p
Procedural outcomes
LOS ED, hours, [median (IQR)]a 5.2 (3.6–7.2) 4.6 (3–6.7) 4.8 (3.1–6.8) 0.091
LOS hospital, days, [median (IQR)] 6.0 (3.1–8.9) 5.8 (2.9–10.3) 5.8 (3–9.9) 0.619
Hospitalisation, [n (%)] 146 (92.4) 378 (90.2) 524 (90.8) 0.417
ICU admission, [n (%)] 60 (38.2) 179 (43.2) 239 (41.9) 0.278
Total ED resource consumption, tax points, [median (IQR)] 1274 (708–1942) 1111 (604–1795) 1177 (632–1828) 0.091
Clinical Outcome
In-hospital mortality, [n (%)] 11 (7.0) 21 (5.1) 32 (5.6) 0.370
Abbreviations: ED emergency department, DOAC direct oral anticoagulants, IQR interquartile range, VKA Vitamin-K antagonist, LOS length of stay. a present in 534
(92.4%) consultations
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Outcomes
No significant differences were found in the investigated
outcomes between the DOAC and VKA group. The hos-
pitalisation and ICU transmission rates were high, a
finding that is explained by the high number of GIB and
intracranial bleedings in both groups needing close clin-
ical monitoring or further invasive therapies.
Limitations
Due to the limitations imposed by the size of the study
and the retrospective design, there are potential
confounders that were not considered in our study. Fur-
thermore, despite the adequate documentation of com-
plications in a tertiary hospital setting and high number
of patients on both anticoagulant group, it is possible
that the group sizes were still not sufficient in order to
find differences in infrequent outcomes such as in-
hospital mortality. Because of the monocentric design
transferability to other settings is only possible to a lim-
ited extent and should be performed carefully. These
limitations are not unique to our study, but rather apply
to most observational pharmacoepidemiologic studies.
Investigation of real-word data can be an important
complement to randomized-controlled-trails, however,
conclusions must be drawn with great caution due to
the uncontrolled confounding factors [13, 14]. Also, we
had no information on the chronicity of CKD or on the
duration of the anticoagulation therapy. A single creatin-
ine obtained during emergency admission can only pro-
vide a snapshot of the patient’s renal function. The same
applies for the INR values, e.g. after reversal of VKA
with PCC. Furthermore, levels of DOAC or aPTT were
not measured routinely over the study period, thus the
decision how to treat a patient on DOAC was often
based on anamnestic data of DOAC intake. There is
growing evidence, that NOAC level measurements
should be standard practice, especially in at-risk popula-
tions such as patients with renal insufficiency [29].
It is well known that decisions in emergency patients
have to be based on often incomplete findings and have
to be made under time pressure, which does not allow
the detailed collection of follow-up parameters [30–32].
In line with the local prevalence of anticoagulant medi-
cations most investigated patients were admitted on riv-
aroxaban [2]. Thus, separate analysis or comparison of
different DOAC or stratified presentations of the out-
come by GFR group was not possible due to small num-
bers of patients in those subgroups. With the fast
adoption of DOAC including elderly patients over the
study years, more DOACs were subscribed to patients
with pre-existing conditions and therefore at risk for an
impaired kidney function and bleedings. With our data,
the exact impact on the results cannot be stated. How-
ever, in our opinion, the main findings of a lower
proportional incidence of intracranial haemorrhage,
more emergency endoscopies and less interventional
therapies in DOAC patients remain untouched by this
finding.
Conclusion
Compared to VKA, emergency admissions due to acute
haemorrhage on anticoagulation therapy with impaired
renal function on presentation on DOAC therapy had a
lower incidence of intracranial haemorrhage. GIB in
DOAC patients needed a higher number of gastroduode-
noscopies but less interventional therapies to stop the
bleeding compared to VKA therapy.
Further prospective multi-centre research in the spe-
cial patient population of patient with impaired renal
function including DOAC level measurements is neces-
sary. Recent developments with specific antidotes and
rapidly and readily available level measurements may
optimize future therapy in this special patient
population.
Abbreviations
CKD: chronic kidney disease; DOAC: direct oral anticoagulant; ED: emergency
department; GFR: glomerular filtration rate; ICU: intensive care unit;
IQR: interquartile range; LOS: length of stay; VKA: vitamin K antagonists
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